Type-specific herpes simplex virus-1 and herpes simplex virus-2 seroprevalence in Romania: comparison of prevalence and risk factors in women and men

AbstractObjectiveTo determine herpes simplex virus (HSV)-2 and HSV-1 seroprevalence in women and men in Romania.MethodsA cross-sectional seroprevalence survey was conducted between 2004 and 2005 on a total of 1058 women and men representative of the population of Bucharest. All participants were aged 15–44 years and completed a structured questionnaire. A blood sample was collected to detect IgG anti-HSV-1 and HSV-2 serum antibodies using the HerpeSelect ELISA (Focus Diagnostics).ResultsA total of 761 women (median age 29 years) and 297 men (median age 29 years) were included. Overall, HSV-2 seroprevalence (15.2%) increased with age. Among women, HSV-2 seroprevalence increased from 11.0% in 15–19-year-olds to 38.3% in 40–44-year-olds. Among men, seroprevalence increased from 4.0% in 20–24-year-olds to 27.1% in 40–44-year-olds. HSV-2 seroprevalence was significantly higher among women than men (17.0% vs. 10.8%). HSV-1 seropositivity was high (87.2%) in all age groups, with no clear trend by age or by sex. In addition to older age and female sex, risk factors for HSV-2 included greater number of lifetime sexual partners, lower educational attainment, and history of genital vesicles. Lower educational level and rural residence were associated with a higher risk of HSV-1 seropositivity.ConclusionsIn Romania, HSV-2 seroprevalence was higher in women than men, and was within European limits and lower than that in Africa and the USA. In contrast, HSV-1 seroprevalence was generally higher than that previously recorded in similarly aged populations in Western Europe

Is kurjak antenatal neurodevelopmental test ready for routine clinical application? Bucharest consensus statement

Background: While two-dimensional ultrasound (2D US) is used only for the assessment of fetal startles and gene ral movements, introduction of Kurjak antenatal neuro developmental test (KANET) by four-dimensional ultrasound (4D US) enabled assessment of not only movements but also some signs used in postnatal neurological assessment like cranial sutures, head circumference and finger movements of the hand for the detection of neurological thumb (adducted thumb in the clenched feast). Overall impression on general movement called by Prechtl ‘Gestalt perception’ is also a part of KANET assessment. These parameters cannot be assessed by 2D US, and according to our opinion they are making the difference enabling more accurate and functionally more reliable assessment of the young and immature CNS. After Osaka standardization of KANET has been published, many studies on fetal behavior from different centers using this method have been conducted and published. Although there is lack of long-term follow-up of children who were assessed by KANET as fetuses, some conclusions on the usage of KANET test in clinical practice can be made. There are still inconclusive results of prenatal neurological assessment using KANET test in fetuses with borderline scores, although it was revealed that negative predictive value of the test as well as inter-observer reliability were satisfactory and acceptable. Conclusion: It can be concluded that KANET test can be used in everyday clinical practice for the follow-up of fetuses at neurological risk with the strong recommendation for strict and reliable multidisciplinary postnatal follow-up till the corrected age of at least 3 years and longer whenever appropriate. This will enable to make better correlation of prenatal KANET scores with postnatal neurodevelopmental outcomes. © 2015, Jaypee Brothers Medical Publishers (P) Ltd. All rights reserved

Multicentric studies of the fetal neurobehavior by KANET test

Assessment of fetal neurobehavior and detection of neurological impairment prenatally has been a great challenge in perinatal medicine. The evolution of four-dimensional (4D) ultrasound not only enabled a better visualization of fetal anatomy but also allowed the study of fetal behavior in real time. Kurjak Antenatal Neurodevelopmental Test (KANET) was developed for the assessment of fetal neurobehavior and the detection of neurological disorders, based on the assessment of the fetus by application of 4D ultrasound in the same way that a neonate is assessed postnatally. KANET is a method that has been applied for the past 10 years and studies show that it is a strong diagnostic tool and can be introduced into everyday clinical practice. We present all data from studies performed up to now on KANET. © 2017 Walter de Gruyter GmbH, Berlin/Boston

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, 1, and 12 (n = 403). HPV-16 and -18 antibodies were measured by enzyme-linked immunosorbent assay at months 0, 2, and 7 or 13 (depending on group); noninferiority evaluation was performed sequentially for seroconversion rates and geometric mean antibody titers. Primary analysis of immunogenicity was based on the according-to-protocol cohort. Vaccine safety and reactogenicity were assessed on the total vaccinated cohort. RESULTS: Predefined noninferiority criteria were met 1 month after the third vaccine dose when the HPV-16/18 vaccine was administered according to the 0-1-12 month schedule compared with the 0-1-6 month schedule in terms of seroconversion rates for HPV-16 (100% and 100%) and HPV-18 (99.7% and 100%) and geometric mean antibody titers for HPV-16 (11884.7 and 10311.9 ELISA units/mL) and HPV-18 (4501.3 and 3963.6 ELISA units/mL), respectively. The HPV-16/18 vaccine had a clinically acceptable safety profile when administered according to either schedule. CONCLUSIONS: The third dose of the HPV-16/18 vaccine can be administered any time between 6 and 12 months after the first dose, with adequate immunogenicity and a clinically acceptable safety profil

Multi-center results on the clinical use of KANET

An extensive review of the literature on the diagnostic and clinical accuracy of Kurjak's antenatal neurodevelopmental test (KANET) and the summarized results of the multi-center study involving 10 centers revealed that four-dimensional ultrasonography (4D US) has become a powerful tool and KANET a valuable test that empowers the clinicians worldwide to evaluate the fetal behavior in a systematic way and contribute to the detection of fetuses that might be at high risk for neurological impairments and in particular cerebral palsy (CP). After 10 years of clinical use, many published papers and multi-center studies, hundreds of trained physicians and numerous tests performed all over the world, KANET has proven its value and has been showing encouraging results so far. The aim of this paper is to show the results from the studies done so far and to reveal the clinical value of the KANET. We expect that data from the larger ongoing collaborative study, the short- and long-term postnatal follow-up will continue to improve our knowledge. Ultimately, we all strive to prevent the CP disorders, autism spectrum disorder (ASD) and other neurological impairments and we are convinced that KANET might be helpful in the realization of this important aim. ©2019 Walter de Gruyter GmbH, Berlin/Boston 2019